GC Aesthetics® (GCA), a privately-held medical technology company specializing in aesthetic and reconstruction solutions, has announced the launch of an extensive, multi-center, prospective clinical study across Europe. This study aims to evaluate and confirm the safety, effectiveness, and patient satisfaction of its innovative PERLE™ smooth opaque round breast implant.
GC Aesthetics® (GCA) has launched an extensive, multi-center clinical study across Europe to evaluate the safety, effectiveness, and patient satisfaction of its innovative PERLE™ smooth opaque breast implant. The study involves leading surgeons from the NHS and private clinics in the UK, as well as private practices across Europe, ensuring a diverse dataset that covers both cosmetic and reconstructive indications.
“Our goal is to generate high-quality clinical evidence to provide valuable insights into the performance and patient benefits of the PERLE™ implant, ultimately setting a new standard for breast implant technology and patient care,” said Chris Brotherston, Head of QA/RA and Clinical Affairs at GC Aesthetics.
The PERLE™ implant features proprietary surface technology (BioQ™) and GCA’s advanced gel technology (Emunomic™ Breast Tissue Dynamic Gel), enhancing safety while maintaining the excellent safety record GCA is known for. This innovative implant is designed to provide long-term, reliable results, and the ongoing study will help reinforce its safety and efficacy for both cosmetic and reconstructive procedures.
“PERLE™ is a groundbreaking implant, and the long-term data collected in this study will empower patients and clinicians to make informed decisions with confidence,” said Ms. Nabila Nasir, Consultant Breast and Oncoplastic Surgeon. “The study involves extensive data collection with a large sample size, ensuring robust and comprehensive insights.”
This clinical research reflects GCA’s commitment to sustainable growth through clinically validated innovation. The findings will not only enhance GCA’s product portfolio but also reinforce its reputation for providing high-quality, safe, and patient-centered solutions. By investing in long-term clinical studies, GCA aims to continue positioning itself as a trusted partner for healthcare providers and women worldwide.
Carlos Reis Pinto, CEO of GC Aesthetics, emphasized the company’s dedication to innovation and evidence-based advancements. “This study highlights our strategic focus on meeting the evolving needs of patients and surgeons globally. We’re committed to advancing breast implant technology while ensuring safety and patient satisfaction.”
Through this initiative, GCA demonstrates its leadership in the aesthetic and reconstructive implant market, underscoring its commitment to delivering solutions that combine cutting-edge technology with rigorous clinical evidence.
